The KD Pharma Quality Control team has achieved the first place in the AOCS Laboratory Proficiency Program for GOED Nutraceutical Oils.
News
0
60% reduction of carbon emissions at our production sites in Germany
Our process engineering team achieved a 60% reduction in CO2 emissions by optimizing our manufacturing process at our two production sites in Bexbach, Germany.
New R&D laboratory and offices expansion
We are pleased to announce the opening of our new R&D laboratory and offices at our world-class synthesis and fractionation facility in Seal Sands, UK.
KD Pharma VP of sales, Uwe Westeppe, was interviewed at DCAT week
“We can support customers over the whole life cycle of their products from process development, piloting, and commercial production,” says Uwe.
KD PHARMA FURTHER EXPANDS ITS CDMO CAPABILITIES IN THE UK MANUFATURING SITE
The new modern plant followed a fast-track build project and triples the capacity of the site.
KD Pharma Group Acquires 51% Stake in Trigal Pharma
Trigal Pharma is a company specialized in clinical research, development and marketing of medical cannabinoids
KD Pharma Group Welcomes Daniel Wiley as Vice President of Special Projects
Daniel will lead growth projects in algal omega-3 lipids, cannabinoids and phytochemicals.
KD Pharma Acquires Phytoextract and CBD Manufacturing Assets
Transaction advances KD Pharma’s cannabinoid manufacturing strategy
KD Pharma Acquires Rohner AG Manufacturing Assets
Acquisition expands KD Pharma’s CDMO capabilities
New MOVE3®: kd-pür® Omega-3 + NEM® Combo Study Confirms Fast Efficacy in Pain & Stiffness Treatment in Healthy Adults
KD Pharma Group SA and Stratum Nutrition® announce their recent partnership to develop a unique joint health formula combining Stratum's NEM® brand eggshell membrane and KD Pharma's kd-pür® marine omega oils. The combination product is being marketed as MOVE3® and sold in softgels via Stratum and KD's global sales forces.
KD PHARMA GROUP & SLA PHARMA INITIATE CLINICAL TRIAL FOR COVID-19
New drug candidate EPAspireTM is shortly entering clinical trials as a promising candidate to treat patients with symptoms of the novel coronavirus infection.
KD PHARMA BEGINS PRODUCTION OF HAND SANITIZER TO HELP GERMANY GO THROUGH THE COVID-19 CRISIS
KD Pharma Bexbach GmbH is dedicating part of its Omega-3 production assets to produce hand sanitizer to help the German community.
GP-Led Single-Asset Secondary
Capiton AG closes single-asset secondary transaction of KD Pharma Group SA and raises new single-asset fund.
KD PHARMA STRENGTHENS ITS TECHNOLOGY PLATFORM BY ACQUIRING UK MANUFACTURING SITE
Acquisition allows KD Pharma to further expand its leading position in the omega-3 pharmaceutical market
KD Pharma Group Refinances €150 Million Debt Facilities
The KD Pharma Group has rearranged and expanded its debt facilities, raising €150 million in total financing through the facilities. The solution includes a term loan to refinance existing debt, a capex facility for production expansion as well as a revolving credit facility.
Introducing Kardio3 for Hearth and Bone Health
“Protect. Restore. Support.”
Kardio3 is a Omega-3 blend with Vitamin K2 and Phytosterols
KD Nutra announce completion of a clinical trial for its Move3™ omega-3 joint formulation
Omega-3 and sports performance – Clinically proven formula Move3™ improves pain, stiffness and cartilage damage related to exercise
KD Nutra is pleased to share exciting news with you about our Move3™ joint health formulation. A recently completed clinical trial has shown that the omega-3 and NEM eggshell membrane formulation has a significant impact in sports performance and exercise recovery.
The Importance of Omega-3 Intake During Pregnancy
Omega-3 fatty acids are essential and can only be obtained from the diet. However, the standard western diet is severely deficient in these critical nutrients. This Omega-3 dietary deficiency is compounded by the fact that pregnant women become depleted in Omega-3s because the fetus uses Omega-3s for its nervous system deployment.
Alpha & Omega Prenatal: Supports Healthy Development that Last a Lifetime
Choline and DHA Omega3 fatty acid have been both studied for their importance on early neural development. Supplementation with Alpha and Omega prenatal vitamin ensures sufficient amounts of these vital nutrients for every woman and her baby.
New Name, Expanded Leadership: KD Nutra
Beginning on November 1, 2018, Marine Ingredients and InnovaGel combined systems to become a unified brand called KD Nutra.
ReGen3™ Next Generation Omega-3 with Pre-Resolving Mediators
Building on the substantial health benefits of EPA and DHA Omega-3 fatty acids, ReGen3™ is an enhanced marine lipid concentrate with enriched levels of pre-resolving mediators (PRMs) that may offer superior efficacy from Omega-3 supplementation. PRM’s are metabolites of Omega-3s that are further converted into active compounds that widely mediate many of Omega-3s known biological actions and functions. Naturally found at low levels in marine lipids, the KD Pharma Group uses our proprietary fractionation methods to create high PRM enriched ingredients.
NutraSolve3 is in the news!
Marine Ingredients, a KD Pharma Group Company, has brought to market an ingredient called NutraSolve3, made from fresh caught livers of Bering Sea cod.
The oil is touted for its vitamin A and D content, as well metabolites it refers to as 'pre-resolving mediators'.
Move3 is in the news!
Omega-3 and… eggshells? New joint support ingredient positioned for active individuals hits the market
NBJ Award: Large Company Growth Marine Ingredients’ 2016 merger with KD Pharma made for a successful 2017
A company’s success or failure certainly can float on the product category a business is in, but at the end of the day it’s people that run the business, and top-shelf people can help make a business viable and profitable for the long term. So it is with Marine Ingredients, a pioneer in the omega-3 fish oil business and the No. 3 omega ingredient supplier in the world—and this year’s NBJ Large Company Growth Award recipient.
KD Pharma Group invests in Nutriceutical Holdings
June 1, 2017 – Blue Bell, Pennsylvania – Nutriceutical Holdings (NH), parent company of Physician Recommended Nutriceuticals (PRN) and Veterinarian Recommended Solutions (VRS), and KD Pharma Group have decided to join forces through a direct investment in Nutriceutical Holdings by KD Pharma Group. KD Pharma Group will become the largest shareholder in Nutriceutical Holdings with the option to acquire the entire company.
KD Pharma Group receives Sustainability Award for Fish Oil from Friend of the Sea
Geneva Switzerland – May 10, 2017. Friend of the Sea certification program contributes to the health of the oceans by assessing and promoting sustainable fishing practices. Friend of the Sea recognized KD Pharma with this award due its years of leadership in sustainable sourcing of raw materials and continued commitment to advocating for transparency and sustainable practices in worldwide fisheries.
KD Pharma Group Company Marine Ingredients launches global Nutraceutical business at the 2017 VitaFoods Europe Nutraceutical Convention.
Geneva Switzerland – May 9 2017 Marine Ingredients, A KD Pharma Group company announced today at the VitaFoods Exhibition in Switzerland that it has expanded its organization to support the global omega-3 nutraceutical market.
KD Pharma announces merger with Marine Ingredients
Bexbach, Germany/Mt. Bethal, PA – October 24, 2016 – KD Pharma and Marine Ingredients announced this week that the two companies will be merging, with anticipated completion during the 4th Quarter of 2016.